United Therapeutics (NASDAQ:UTHR) Shares Gap Up on Analyst Upgrade

Shares of United Therapeutics Corporation (NASDAQ:UTHR) gapped up before the market opened on Monday after HC Wainwright raised their price target on the stock from $600.00 to $660.00. The stock had previously closed at $522.83, but opened at $605.22. HC Wainwright currently has a buy rating on the stock. United Therapeutics shares last traded at $595.7250, with a volume of 438,978 shares traded.

A number of other research firms have also recently weighed in on UTHR. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Wells Fargo & Company raised their price objective on United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a report on Tuesday. Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. UBS Group upped their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Finally, Bank of America increased their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $586.00.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $471.91, for a total value of $10,617,975.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total value of $4,654,145.00. Following the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $63,688.30. This represents a 98.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 333,820 shares of company stock valued at $165,495,478. 10.30% of the stock is owned by corporate insiders.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 Phase 3 success — The pivotal TETON‑1 study met its primary endpoint, showing a clinically meaningful FVC improvement (Hodges‑Lehmann estimate ~130.1 mL vs placebo at 52 weeks), supporting Tyvaso’s potential expansion into IPF and a likely regulatory path. BusinessWire: TETON‑1 Results
• Positive Sentiment: Wall Street upgrades and target lifts — Multiple firms raised price targets (TD Cowen, HC Wainwright, BofA, TD Cowen to ~$660 among others), reflecting materially higher revenue/market‑expansion assumptions if Tyvaso wins an IPF label. TickerReport: HC Wainwright Raise
• Positive Sentiment: Buyback / ASR and ralinepag momentum — Recent company buyback authorizations (including accelerated share repurchase activity) and positive Phase 3 ralinepag data (PAH) add to near‑term shareholder‑return dynamics and reduce share count risk. QuiverQuant: Buyback & Ralinepag
• Neutral Sentiment: Heavy call‑option activity and volume — Unusually large call buying and above‑average equity volume indicate speculative positioning and short covering; this can amplify moves short term but is not a fundamental read‑through by itself.
• Neutral Sentiment: Mixed analyst stances — Some firms raised targets but kept neutral/equal‑weight ratings (e.g., Wells Fargo, BofA), signaling differing views on how much IPF uptake and pricing convert to durable earnings. 24/7 Wall St.: Dual Target Hikes
• Negative Sentiment: Valuation and execution risk cautions — Some analysts note that strong trial momentum is partially offset by high valuation and execution/regulatory risk (commercial rollout, payer uptake), which could limit further multiple expansion. TipRanks: Balanced View
• Negative Sentiment: Large insider selling flagged — Public filings compiled by data providers show extensive insider sales over recent months; investors often view concentrated insider selling as a negative signal to monitor. QuiverQuant: Insider Activity
• Negative Sentiment: Questions about sustainability of the move — Some market commentaries (and earnings‑estimate trends) warn the post‑trial pop may not sustain unless follow‑on commercialization, label, and payer access dynamics become clearer. Zacks: Will Strength Last?

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. grew its holdings in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the period. Choreo LLC purchased a new position in United Therapeutics during the second quarter worth about $220,000. Elevation Point Wealth Partners LLC acquired a new position in United Therapeutics in the 2nd quarter valued at about $53,000. Northwestern Mutual Wealth Management Co. lifted its stake in shares of United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of United Therapeutics during the 2nd quarter worth $136,453,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

The stock has a market capitalization of $25.99 billion, a price-to-earnings ratio of 21.25, a P/E/G ratio of 2.12 and a beta of 0.84. The business has a 50-day moving average of $500.92 and a 200-day moving average of $476.29.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the firm earned $6.19 EPS. Equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.